Skip to main
MMSI

MMSI Stock Forecast & Price Target

MMSI Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Merit Medical Systems is expected to continue its growth through new product launches and acquisitions, as well as its Continued Growth Initiatives program. With an expected organic revenue growth of 6-8%, and a strong balance sheet, the company is well-positioned for future success and potential M&A opportunities. While there is some risk involved in terms of margin performance and slower growth in China, the company's disciplined approach to M&A should mitigate these risks. Overall, the outlook for Merit Medical Systems is positive, with a base case scenario of a 6-8% organic revenue growth and a potential bull case scenario of 9% or higher growth.

Bears say

Merit Medical Systems is currently facing significant challenges with their Cardiovascular segment, as the majority of their revenue is earned from this segment and the recent acquisitions may not be able to drive above-corporate average growth. Additionally, the company's free cash flow has seen a decline in recent years and their net leverage ratio remains high, potentially limiting their ability to invest in growth opportunities. Furthermore, while the launch of the WRAPSODY Cell-Impermeable Endoprosthesis may contribute to revenue growth and margins, it is uncertain how well the product will perform in the market and if it will meet company expectations.

MMSI has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merit Medical Systems (MMSI) Forecast

Analysts have given MMSI a Buy based on their latest research and market trends.

According to 8 analysts, MMSI has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merit Medical Systems (MMSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.